Zaradi visoke učinkovitosti prekinili klinično študijo zdravila za zdravljenje raka prostate

In zakaj potem farmacija potem ne izda da smo dobili cepivo proti HIV kot so to počeli za nore krave?

enadvatri je 11. jun 2012 ob 15:24 izjavil:

Virusa HIV še ne znamo pokončati (pri ljudeh) z zdravili, žal.

Nekateri Afričani so razvili precej močan odziv, s katerim se precej zmanjša št. virusov v organizmu, a še vedno je virus močnejši.

Znan je primer iz Francije, ko so HIV pozitivnemu bolniku zaradi levkemije presadili kostni mozeg od donatorja. Kasneje so opazili upad št. virusov, ki je napredoval do nezaznavnega pragu, test na imunski odziv pa je še reaktiven. Kolikor vem, je to najobetavnejše odkritje doslej.

Mimogrede, zarot ni; so samo interesi na vseh straneh.

This hypothesis was tested in an AIDS patient who had also developed myeloid leukemia, and was treated with chemotherapy to suppress the cancer. A bone marrow transplant containing stem cells from a matched donor was then used to restore the immune system. However, the transplant was performed from a donor with 2 copies of CCR5-Δ32 mutation gene. After 600 days, the patient was healthy and had undetectable levels of HIV in the blood and in examined brain and rectal tissues.[18][19] Before the transplant, low levels of HIV X4, which does not use the CCR5 receptor, were also detected. Following the transplant, however, this type of HIV was not detected either, further baffling doctors.[19] However, this is consistent with the observation that cells expressing the CCR5-Δ32 variant protein lack both the CCR5 and CXCR4 receptors on their surfaces, thereby conferring resistance to a broad range of HIV variants including HIV X4.[20] After three years, the patient has maintained the resistance to HIV and has been pronounced cured of the HIV infection.[21]

RejZoR je 9. jun 2012 ob 12:40 izjavil:

Za raka so predvsem krive rakotvorne kemijske spojine, težke kovine, toksini, elektromagnetno sevanje (sicer nepotrjeno ampak najverjetneje ima tudi vpliv). Pač stvari, ki škodijo celični strukturi in ki povzročijo, da slednje ponorijo in ven dobiš gmote celic, ki niso take kot bi morale biti.

For the current trials, he is only looking for people with low-grade lymphoma regardless if they have been previously treated. He said Stanford is planning on running two trials by the end of the year with a total of about 35 test subjects.

She said CAR-T is both labor intensive and very expensive -- drugs alone cost half a million dollars -- but that the new immunotherapy treatment has raised survival rates from about 10-15 percent to more than 60 percent.

But CAR-T comes with its fair share of side effects: fever, confusion, organ failure and the chance of permanent loss of one's B cells -- responsible for producing antibodies. "It's not a trivial therapy," Hermiston said.